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Abstract
Farnesoid X receptor (FXR) is a nuclear transcription factor that is activated by bile 
acids in the liver and intestine and regulates bile acid homeostasis, glucose and lipid 
metabolism. Direct FXR activation by a ligand has been identified as a therapeutic 
modality for a range of liver and metabolic diseases. FXR activation studies have 
exclusively been conducted in mouse models, which are of limited human relevance due 
to species differences between mice and humans in bile acid composition, metabolism 
and FXR activation patterns. The ileal bile acid transporter (IBAT) is pivotal for the 
reabsorption of conjugated bile acids from the ileum back to the liver and an important 
FXR target gene. FXR activation leads to reduction in hepatic bile acid synthesis via 
secreted FGF19. IBAT inhibition indirectly represses intestinal FXR by interruption of 
the enterohepatic circulation of bile acids, and this concept has been tested in the 
treatment of cholestatic itch, fatty liver disease and dyslipidemia.
In paper I, we explored whether pharmacological inhibition of IBAT might ameliorate 
cholestatic pruritus in patients with primary biliary cholangitis. Despite some subjective 
improvement, the study needed to be prematurely stopped due to abdominal side effects. 
In paper II, we examined how FXR activation by obeticholic acid (OCA) impacts on 
gallbladder physiology in patients awaiting gallstone surgery. We found that OCA 
increased the risk for gallstone formation, by decreasing biliary bile acids, with 
concomitant increases in cholesterol saturation and bile acid hydrophobicity indices, 
and increasing biliary fibroblast growth factor 19 (FGF19).
In paper III, we investigated OCA effects on FXR-DNA binding sites in patients 
awaiting bariatric or gallstone surgery. We found by performing ChIP-Seq that the 
expression of FXR-DNA binding sites was not related to OCA-treatment; rather, it 
seems to be predetermined by the phenotype (obese vs non-obese). In contrast, RNA-
Seq indicated induction of FXR target genes by OCA as compared to placebo. 
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